Eugene Schaefer
Senior Director, API Large Molecule Pharmaceutical Development & Manufacturing Sciences, Johnson & Johnson
Talks in this session will include new approaches to process development in both upstream and downstream areas that together present significant improvements to speed in the development and implementation of commercial drug substance processes. The use of automation and high-throughput systems, accelerated learning through data capture and mining, more reliable scale-down models and potentially disruptive technologies are examples of topics that should be considered for talks and discussion.
Brian Kelley, Genentech
Nigel Titchener-Hooker, University College London